How a DPIA Was Implemented in a Blockchain-Enabled Oncology Trial

What Is a DPIA and When Is It Required?

A Data Protection Impact Assessment (DPIA) is a mandatory tool under the General Data Protection Regulation (GDPR) when processing activities are likely to result in high risk to individuals’ rights and freedoms. For clinical trials, this includes the use of:

• 💻 eConsent and mobile health apps
• 🔐 Biometric data or genetic profiling
• ⚙️ Blockchain or AI-based platforms
• 🌎 Cross-border data transfers outside EU/EEA

A DPIA identifies potential data risks and defines actions to minimize those risks before processing begins. Regulatory authorities expect documented DPIAs in the TMF, particularly for decentralized or tech-enabled trials.

Case Background: Phase II Oncology Trial Using Blockchain for eConsent

A mid-sized sponsor initiated a Phase II multicenter oncology trial targeting advanced breast cancer patients. The trial incorporated:

• 📱 Mobile-based eConsent platform using biometric signature
• 🔒 Ethereum-based smart contracts for consent timestamping
• 🚀 Data hosting on hybrid EU-U.S. infrastructure
• 🤵 Third-party analytics using de-identified patient data

Given the sensitivity of cancer data and the novel use of blockchain, the sponsor’s Data Protection Officer (DPO) flagged the need for a DPIA under Article 35 of the GDPR.

DPIA Process Initiation and Governance

The DPIA was initiated during the vendor qualification and protocol design stage. Key steps included:

1. Assigning DPIA Ownership: The QA Director acted as DPIA coordinator
2. Stakeholder Involvement: Data protection officer (DPO), IT security, clinical ops, and legal were engaged
3. Vendor Input: eConsent and blockchain vendors provided technical documentation
4. Timeline: DPIA was completed within 4 weeks before FPFV

A DPIA template from PharmaSOP.in was adapted to the oncology context.

Identified Risks and Impact Ratings

The DPIA process identified 5 major risk categories using a standard 5×5 risk matrix. Each risk was scored based on:

• ⚠️ Likelihood (1–5)
• 📊 Severity (1–5)
• ❗ Risk Priority Number (RPN = L × S)

Risk Mitigation Measures Taken

• 🔒 Data encryption in-transit and at-rest for all eConsent files
• 📎 SCCs (Standard Contractual Clauses) with U.S. cloud vendor
• 🔄 Off-chain pseudonymization of biometric identifiers
• ✅ eConsent system audit trail for all re-signatures
• 📝 Executed DPAs with third-party analytics vendors
• 👤 Staff trained on re-consent SOP (updated v3.1)

These measures reduced all risks to moderate or low, satisfying GDPR Article 35 requirements. DPIA results were shared with the clinical team and incorporated into site training slides.

TMF Documentation and Inspection Readiness

The completed DPIA and its annexes were filed in Section 8.2.23 of the Trial Master File. Contents included:

• 📑 DPIA main report with risk matrix
• 📁 Vendor technical documentation
• 🛠️ SCCs and signed DPAs
• 📅 DPIA review meeting minutes

During a Q1 2024 EMA inspection, the DPIA was specifically requested by the inspectors and contributed to a favorable compliance outcome. For TMF filing best practices, refer to PharmaGMP.in.

Best Practices for DPIA Execution in Trials

• ✅ Initiate DPIA before FPFV or data collection
• 💼 Include DPO and legal in risk discussions
• 📝 Document all assumptions and limitations
• 📈 Use DPIA output to adjust protocol and vendor agreements
• 📚 Train sites on risk mitigations and subject rights

Conclusion: DPIA as a Compliance and Risk Mitigation Asset

Conducting a DPIA early in the trial lifecycle can not only fulfill GDPR obligations but also proactively identify operational risks. In this oncology case, DPIA enabled smoother cross-border collaboration, transparent consent handling, and preparedness for regulatory scrutiny.

For downloadable DPIA templates and oncology-specific guidance, explore PharmaValidation.in or refer to EMA data protection guidance.